Valuation: Senzime AB

Market Cap 53Cr 5.27Cr 4.79Cr 4.43Cr 4Cr 7.54Cr 495.01Cr 7.81Cr 21Cr 265.64Cr 20Cr 19Cr 841.44Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 53Cr 5.27Cr 4.79Cr 4.43Cr 4Cr 7.54Cr 495.01Cr 7.81Cr 21Cr 265.64Cr 20Cr 19Cr 841.44Cr EV / Sales 2026 *
4.63x
EV / Sales 2027 * 2.88x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -
1 day-3.42%
1 week+1.04%
1 month+26.31%
3 months-14.84%
6 months-23.85%
Current year-37.31%
1 week 3.34
Extreme 3.34
3.88
1 month 2.61
Extreme 2.61
3.88
Current year 2.35
Extreme 2.35
6
1 year 2.35
Extreme 2.35
6
3 years 2.35
Extreme 2.35
9.6
5 years 2.35
Extreme 2.35
24.8
10 years 2.35
Extreme 2.35
28.5
Manager TitleAgeSince
Chief Executive Officer 53 03/05/2023
Director of Finance/CFO 56 01/01/2022
Chief Tech/Sci/R&D Officer 50 01/01/2023
Director TitleAgeSince
Chairman 53 03/05/2023
Director/Board Member 70 01/01/2016
Director/Board Member 63 05/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/09/26 Buy

Director

1,78,388 0.1135%
25/09/26 Buy

Chief Technology Officer

30,000 0.0191%
24/09/26 Buy

Chief Technology Officer

30,000 0.0191%
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%+1.04%-33.76%-50.80% 5.47Cr
-0.99%-2.77%-17.37%+7.17% 19TCr
+0.02%+0.09%+6.86%+37.39% 13TCr
+0.35%-4.61%-13.72%+6.58% 12TCr
+1.18%-4.80%-42.14%+3.55% 9.25TCr
-0.58%+3.23%-2.21%+81.27% 6.85TCr
-0.72%+0.57%+13.35%-7.91% 5.94TCr
-0.51%-0.85%+4.73%+50.15% 5.55TCr
-2.26%+4.42%-3.31%+45.02% 4.96TCr
+1.27%+1.37%+0.71%-1.96% 3.52TCr
Average -0.46%+1.51%-8.69%+17.05% 8TCr
Weighted average by Cap. -0.16%+0.03%-9.03%+21.71%

Financials

2026 *2027 *
Net sales 11Cr 1.14Cr 1.03Cr 95.54L 86.3L 1.63Cr 106.88Cr 1.69Cr 4.55Cr 57Cr 4.27Cr 4.18Cr 181.67Cr 18Cr 1.83Cr 1.66Cr 1.54Cr 1.39Cr 2.62Cr 171.9Cr 2.71Cr 7.32Cr 92Cr 6.87Cr 6.72Cr 292.19Cr
Net income -6.71Cr -66.47L -60.39L -55.8L -50.4L -95.11L -62Cr -98.46L -2.66Cr -33Cr -2.49Cr -2.44Cr -106.09Cr -3.65Cr -36.16L -32.85L -30.35L -27.42L -51.74L -34Cr -53.56L -1.45Cr -18Cr -1.36Cr -1.33Cr -58Cr
Net Debt - -
Projected Income Statement - Annual - Senzime AB
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
16/26/16 SEK 3.385 -3.42% 1,49,096
13/26/13 SEK 3.505 -2.50% 2,08,185
12/26/12 SEK 3.595 -4.01% 5,30,494
11/26/11 SEK 3.745 +6.09% 19,40,814
10/26/10 SEK 3.530 +0.28% 2,09,996

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Senzime AB
  1. Stock Market
  2. Stocks
  3. SEZI Stock